I. INTRODUCTION
In discussing the two-signal concept of selflnonself discrimination. Melvin Cohn extolled the virtues of immunological hypotheses that accommodate all relevant observations and therefore enunciate principles. as opposed to concise "small theories" that explain only a few facts [I]. Cohn's points are exemplified by transplantation. which developed throughout much of its modern history in the absence of a unifying general principle. The inability to evolve an encompassing explanation for observations made in human and animal allograft recipients. or in surrogate in vitro models. drove much of transplantation research down the same reductionist pathway as that of its handmaiden. immunology.
The resulting triumph of detail over concept can be traced to two premises that were introduced into the still fragile base of transplantation immunology between 1944 and 1959. The first was that the events following transplantation could be defined in terms of one-way immune reactions: host versus graft (HVG) and graft versus host (GVH). This was a potentially defensible framework from which important experiments could be formulated. However. when the first premise was combined with a second assumption. namely. that whole organ allograft "acceptance" must be by different mechanisms than the chimerism-dependent acquired tolerance. by Billingham. Brent. and Medawar [2.31. the result was derivative dogma that we have called "the one-way paradigm" (4).
THE Y IN THE ROAD: 1962
Ironically. the first examples of successful human renal transplantation were directly responsible for establishment of t he intellectually disorienting one-way paradigm. Until 1959. the production of chimerism by donor leukocyte infusion in preparation for organ allotransplantation had been a much anticipated natural extension [5, 6) of the neonatal tolerance models [2. 3) and the adult rodent ana-
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logues in which recipient conditioning by cytoablation was required for donor celI engraftment [7, 8] . The threat of graft-versus-host disease (GVHD) [9, 10] restricted this strategy to closely histocompatible donor/recipient pairs [5, 6, [8] [9] [10] [11] . However, when long survival of functioning human kidney alIografts was accomplished in sublethally irradiated recipients without donor leukocyte infusion [12] [13] [14] and then regularly (from 1962 onward) with the additional omission of cytoreduction under continuous pharmacological immunosuppression [l [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , both chimerism and the need for recipient cytoablation seemingly had been eliminated as conditions for organ allograft acceptance.
Once this thought was embedded into the catechism of organ transplantation, it was not challenged for the next 30 years. The first casualty of the consensus was a hypothesis by Simonsen [19] and Michie, Woodruff. and Zeiss [20] . who postulated (in 1960-61) that the two populations of immune cells in neonatally tolerant mice managed to coexist in a stable state by becoming mutually nonreactive while retaining the ability to function collaboratively (Le., in a joint immune response to infection). This heretical suggestion presaged the active network hypotheses of tolerance of Jerne [21] , Coutinho [22] , and Cohen [23] .
The Simonsen hypothesis was recanted in 1962 [241, ostensibly because no experimental support could be found for it. More importantly, however, the hypothesis had been advanced in a nonreceptive climate wherein nothing less than clonal deletion was being seriously considered as the explanation for acquired transplantation tolerance. The disputes during the immediately preceding years about clonal selection as the basis for selflnonself delineation seemingly had achieved closure with the ultimate imprimatur of the Nobel Prize, which was awarded to MacFarland Burnet in 1960 [25, 26] .
It was no coincidence that the 1960 colaureate with Burnet was Peter Brian Medawar, whose observations in the neonatal tolerance model (with Rupert Billingham and Leslie Brent [2, 3, 11] ) were widely considered to be a validation of Burnet's prediction that developing lymphocytes with an open repertoire of receptors could be purged of self-reactive cells before they achieved functional maturity. Similar tolerance produced in radiation chimeras [7, 8] also was viewed as an iatrogenically engineered simulation of ontogeny. However, the argument for clonal deletion as the key mechanism of either variety of acquired tolerance was not beyond criticism, as has been pointed out by Schaffner [25, 26] , Cohn [II, Nossal [27] , and Tauber [28] .
All factors considered, it was difficult to envision transplantation as a biologically sound undertaking and. in fact. Burnet did not. In 1961, we wrote in the New England Journal of Medicine that "much thought has been given to ways by which tissues or organs not genetically and antigenically identical with the patient might be made to survive and function in the alien environment. On the whole the present outlook is highly unfavorable to success." [29] .
III. THE ONE-WA Y PARADIGM
A. Organ Transplantation .
Part 01 the appeal of the simplistic one-way paradigm that emerged from the 1959-63 period was the compatibility of this conceptual framework with Medawar's definition ot rejection as a unidirectIOnal host versus defenseless graft (HVG) immune 
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response [30] (Figure I A) . When the one-way in vitro tests of immune reactivity were developed [31.32] , they were automatically accepted as "minitransplant models," the results from which were assumed to be directly applicable to in vivo circumstances.
B. Bone Marrow Transplantation
From the perspective of the early 1960s, it also seemed logical to interpret the tolerance induced in rodents with splenocyte (2.3] or subsequently bone marrow transplantation (3, 7, 8, 11) as transposed examples of the one-way paradigm ( Figure  1B ) in which the GVH reaction mounted by the immunologically competent allograft rejected the defenseless recipient unless there was a high degree of histocompatibility. This frame of reference guided the major histocompatibility complex-(MHC)-limited strategies of recipientcytoablation and "replacement" [7, 8] Thus. as had occurred earlier with the engraftment of human kidneys, the success of clinical bone marrow transplantation strengthened the grip of the oneway paradigm. notwithstanding its inability to explain why organ transplantation was governed by different rules than those for bone marrow transplantation (Table  I) . At the root of the dilemma lay the assumption that chimerism. the sine qua non of bone marrow transplantation. was irrelevant to an explanation of successful organ transplantation.
IV. THE TWO·WAY PARADIGM A. Human Observations
A connection between the chimerism of hematolymphopoietic transplantation and the successful engraftment of whole organs was made with the discovery in 1992 of persistent donor leukocytes (microchimerism) up to 30 years postoperatively in the peripheral tissues or blood of human kidney. liver. and other organ recipients [42] [43] [44] [45] [46] (Figure I C) . The donor cells were few in number. requiring sensitive immunocytochemical and polymerase chain reaction (peR) techniques for detection. Nevertheless. we were able to postulate that the donor-derived leukocytes constituted one limb of antagonistic but ultimately reciprocally attenuated or abrogated HVG (rejection) and GVH reactions [42-471·
In this context. disruption of the leukocyte interaction by the host cytoablation used to prepare bone marrow recipients. but not the recipients of whole organs. was responsible for the disparities in the two different kinds of transplantation (Table  1 ). The cancelling effect of the (WO immunoeyte populations under the conditions of postoperative immunosuppression used for organ transplantation explained the poor prognostic discrimination 01 human leukocyte antigen tHLA) matching as well JS the raritv of GVHD alter the enl!rattment 01 immunologicallv active organs such 
487
as the intestine and liver. It was obvious that the characteristic cycle of crisis and resolution. first observed in drug-immunosuppressed kidney recipients and most practically monitored by serial changes in allograft function [16] , was the product of a dual immune reaction (Figure 2 ). At the same time as the peripheral migration of the donor cells. there was an influx of recipient cells that did not cause graft damage when adequate immunosuppression was given ( Figure IC) [44,45,48-521. If transplantation was successful. both the allograft and the recipient became genetic composites.
It also was proposed that bone marrow and organ transplantation were. in fact. mirror images. resulting from the drastically different treatment strategies [4, 421. This contention has been supported by reports describing a trace residual population of recipient leuKocytes in essentially all human bone marrow recipients. 
B. Experimental Evidence
The microchimerism following organ transplantation has been studied extensively in a variety of rat and mouse allograft models [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] . Although limited tissue or blood sampling of patients bearing organ allografts does not always reveal the microchimerism [44, [70] [71] [72] [73] , the experimental studies have shown that the failure to find donor leukocytes in a long surviving organ allograft recipient simply reflects an inadequate search [59, 66, 67] . The cumulative evidence from the experimental studies has all but eliminated the alternative possibility that the microchimerism may be an effect rather than the cause of organ allograft acceptance [74, 75] . The answer to this "chicken or egg first?" question [76] was the same as in historical investigations of florid chimerism [77] [78] [79] [80] . Also in accord with classical studies, the quantity and lineage composition of the donor leukocytes contained within the transplanted rodent organs strongly influenced their survival in the recipient and determined whether the chimerism that they produced was associated with lethal GVHD or graft acceptance [66] . Nonparenchymal cells of the liver (the most tolerogenic whole organ) resembled bone marrow cell suspensions in that both contained higher numbers of immature leukocytes and cells of myeloid origin than the lymphocyte-rich and GVHD-prone intestinal allograft or allogenic lymph node or spleen cell suspensions [66] .
Thus. the difference between the chimerism produced by classical bone marrow transplantation and that produced by the migratory leukocytes from whole organs has appeared to be largely semantic. dose-dependent. and influenced by the lineage profile of the "passenger leukocytes" contained in the organ allograft. In line with this conclusion. the changes following transplantation to noncytoablated rodent recipients of the hind limb with its rich bone marrow content are much the same as those after engraftment of visceral organs [81) .
c. The Role of Immunosuppression
A protective umbrella of immunosuppression is usually needed for the survival of the minority population [66] (Figures IC and 2 ). However. this may be only a temporary requirement after out bred canine liver [82] and kidney transplantation and in rodent models too numerous to cite of liver. heart. lung, and kidney transplantation. Moreover. the permanent acceptance of liver allografts is possible with no treatment at all in a significant percentage of outbred pigs [87] [88] [89] [90] and several rat strain [91, 92) and virtually all mouse strain combinations [59) . Mouse heart [59, 93] and kidney allografts [94] are also accepted without the need for immunosuppression in a much more limited number of MHC disparate circumstances. In all of these animal models. the allograft passes through an acute selfresolving rcjection on the way' te tolerance. The tolerance induced by the organ variably extends to other donor tissues and organs [59.66.91 -95] despite the fact that antidonor reactivity determined with in vitro tcsting is almost invariably re-(ained (split tolerance) [66.96-981 or can be restored by (he addition of the appro-
Transplantation Tolerance 489 priate cytokines to the cultures. Species-specific tolerogenic effects of the liver also have been demonstrated after hamster ..... rat xenotransplantation [99] .
Organ tolerogenicity also occurs in humans. especially after liver transplantation (44], but at a slower and unpredictable pace. By October 1995, 12 (28070) of our 42 longest surviving liver recipients (13-112 to 26 years post operative) had stopped their immunosuppressive drugs. The nearly equal cumulative duration of the 12 patients off immunosuppression (shaded) and under treatment (shown in black) is evident in Figure 3 . At present. however, it is not possible to determine by immunological testing which patients can be weaned from therapy. In a more recent prospective trial [100] that now includes 95 patients [101] . weaning was started > 5 years post transplantation. In the first 80 cases. in 30% of the recipients. including some with proven microchimerism. rejection developed. necessitating resumption of maintenance immunosuppression (Figure 4 ). Thus. although many of the long surviving MHC mismatched cadaveric human liver recipients no longer need immunosuppression. some probably can never aspire to be drug-free. Even in such patients. however. the disseminated donor-derived leukocytes (and their companion organ) apparently can be maintained for a lifetime under continuous immunosuppression.
The same principles apply with less tolerogenic organs. Discontinuance of immunosuppression is thought to be more dangerous in nonhepatic recipients. Nevertheless. ( Table 2) . Patients 3 and 4, whose mixed lymphocyte reaction (MLR) test results showed a profoundly depressed reaction to donor and third-party targets before drug withdrawal [451, had prompt restoration of response to both in the drug-free state but with no evidence of rejection.
D. The Stem Cell Question
The persistence of multilineage donor cells in human organ recipient tissues for up to 30 years after transplantation has been construed as prima facie evidence of the presence of hematopoietic stem and precursor cells among the donor leukocytes that migrate from the organ allografts (\03,104). This belied the widely held belief that hematolymphopoietic stem cells in adult mammalian life require a bone marrow microenvironment. In interdiction of this axiom, it has been shown that all hematolymphopoietic lineages in supralethally irradiated mice (9.5 Gy) can be reconstituted as efficiently as with bone marrow by the infusion of stem cells isolated from syngeneic adult mouse livers (105) (106) (107) . The contention that stem cells are present in the adult liver and in other organs (but in smaller numbers) has been upheld by direct experimentation. Irradiated rats can be reconstituted with the expedient of orthotopic liver transplantation just as reliably as with bone marrow (108) . Importantly, heterotopic heart transplantation had a therapeutic effect similar to that of 0.5 x let infused donor bone marrow cells or a large blood transfusion, allowing permanent hematopoietic reconstitution of occasional cardiac recipients and prolongation of survival of almost all other [108] . This occasional rescue is increased to nearly 100% by the post-cardiac transplantation administration of Iisofylline (Murase et a1.. manuscript in preparation). This phosphatidic acid inhibitor facilitates bone marrow engraftment by suppressing hematopoiesis-inhibiting cytokines (tumor necrosis factor a (TNF-a). TGF-I3. A. Leukocyte Subsets "T cell tolerance" has been the term used for successful experimental manipulations in a spectrum of highly controlled conditions. There has been much evidence, however, that the T lymphocytes are directed by specialized immune regulatory leukocytes of T cell or unknown lineage (i. 
B. Multimechanistic Hypotheses
Such clues are intriguing, but it is unlikely that allograft acceptance can be fully comprehended from the results of studies of individual leukocyte phenotypes [471. Instead. the events leading to this state suggest learning (cognitive) and intelligence functions of the immune system that are properties of the networks postulated to explain tolerance to nonliving antigens by Jerne [21] . Coutinho [22] . Cohen [23] . The role of the thymic versus peripheral mechanisms [136] in graft acceptance under clinical circumstances has been controversial. The prompt appearance of donor-derived leukocytes in the recipient thymus after organ transplantation was of particular interest because of the strikingly tolerogenic effect in rodents of intrathymic inoculation of donor leukocytes [137, 1381 . However, thymectomy in adult rates does not influence either the chimerism or spontaneous tolerance induced by liver transplantation (63] . Dejbakhsh-Jones et al. [139] have shown that after thymectomy and lethal irradiation in adult mice reconstituted with purified hematolymphopoietic stem cells. ap T cells developed no differently than in control animals except for a reduced proportion in the spleen. Between 1962 and 1965. 32 patients. including 24 who were part of a controlled randomized trial. underwent transthoracic thymectomy from 8 to 112 days (average 22) before renal transplantation from living related or unrelated donors. After 3-112 to 7 years, no clinical differences were apparent between the thymectomized and control recipients. although there was a trend to better histopathological findings in the thymectomy group [140J. In 1992. comprehensive in vitro immunological studies of many of the remaining recipients and their donors did not reveal any distinguishing features of one cohon versus the other (Gene Shearer and Adriana Zeevi. unpublished observations). After 25 to 30 years. the thymectOmized patiems had no clinical advamage or disadvantage.
O. The Parking Models
Although parking experiments have been put to good use in transplantation research [141. 1421. the altered (nonreactive) leukocytes that -repopulate an organ during residency in the imermediary allogenel\; host disqualifv the graft's relranspiamallOn for qudy of complex tolerance mechantsms. In addition. the leukocyte replacement Juring the parking penod is nor complete. Evcn at I year of residcnce 10 a IOlcrant recipient, IOOJo of the nonparenchymal cells (NPCs) remain donor, a proportion that is essentially fixed from day 100 onward [56] . Not surprisingly, the results after the second-stage procedure have been uninterpretable [69, 143] .
In simpler experiments involving only the depletion of organ leukocytes by donor irradiation, both the tolerogenicity and antigenicity of heart [135] and liver allografts [68] are abrogated or weakened. Tolerogenicity can be restored by an infusion of donor strain splenocytes 24 hours before the organ is removed for transplantation [144] . The necessary presence of donor leukocytes for tolerogenicity also has been unequivocally shown with pancreatic islet transplantation into the thymus [137] and in several other related models.
VI. WHAT IS HUMAN TRANSPLANTATION TOLERANCE?
Permanent drug-free graft acceptance after a course of immunosuppression usually is termed "operational tolerance" to distinguish it from the ostensibly pristine neonatal tolerance of Billingham, Brent, and Medawar [2, 3] . However, Streilein has demonstrated not only how heterogeneous the outcome in the acquired neonatal tolerance model actually is, but how uncommon it is to achieve a state resembling complete donor-specific clonal deletion [145] . Alard et al. [146] have recently shown in these chimeric animals that the ability of donor-derived leukocytes to proliferate in response to a skin graft challenge was a more critical determinant of tolerance outcome than the baseline level of chimerism. This was only the latest evidence that transplantation tolerance is an active nondeletional process. Is the ability of a human allograft recipient to discontinue immunosuppression successfully long after either organ or bone marrow transplantation fundamentally different from the gold standard tolerance that is so easy to produce with inbred rodent models? We do not think so. When we determined donor-leukocyte chimerism to be present up to 30 years post transplantation in our organ recipients. we realized that all examples of allograft "acceptance," whether immunosuppressiondependent or not, were variations on the theme originally described by Billingham, Brent, and Medawar [2, 3] .
With this finding, it was possible to define both success and failure after transplantation in a different way than before. Success "(whether described as) tolerance or graft acceptance (meant) that a characteristic lymphoid and dendritic cell chimerism had been introduced which may be stable either without further treatment, or only when continued immunosuppression is provided" (42). Failure connoted a state in which "an unstable graft and its migrated cells may either be rejected or cause GVHO" (421. It required no imagination to see the uninterrupted thread of chimerism from the observations by Owen (1471 of natural tolerance in freemartin cattle to the donor-derived leukocytes found nearly a half century later in human and animal recipients of organ allografts. Between these brackets lay the rodent neonatal [2.3) . cytoablation-dependent [7. 81. parabiosis-induced [148) . and more complicated "mixed chimerism" tolerance models (Figure 5) .
One 01 the lessons emphasized in our first [42) and all subsequent reports of organ transplantation-associated chimerISm was that the rapidly evolving drug-free ,.
Transplantation Tolerance 495 donor-specific tolerance induced with donor leukocytes in a few days in rodent models could not be extrapolated to unrealistic clinical expectations [76, 103] . In clinical practice, the duration of mutual exposure of the two cell populations necessary permanently to prevent one of the response arms from destroying the other has been widely variable, as was illustrated by the liver transplantation weaning trials. Moreover, there has been no way, except by trial and error, to determine the amount of immunosuppression required during this period. There has not been evidence that increasing maintenance drug dosage above the requisite threshold level can accelerate the events leading to tolerance; it is likely that excessive therapy may prevent achievement of this objective.
Thus, immunosuppressive agents, which have diverse sites of action [152] , do not cause tolerance, but rather permit it with variable success by allowing an alternative normal function of the immune system to be expressed. Chimerism and the derivative state of tolerance are almost contemporaneous in numerous rodent models of liver transplantation ( Figure 6 ). In contrast, the cause (chimerism) and the effect (tolerance) are separated by months or years when liver transplantation is performed in out bred animals and humans (Figure 6) , no matter what the means of immunosuppression. In many cases, the desired drug-free end point may never be reached. Chimerism (and its companion allograft) can nevertheless be maintained for the lifetime of such patients under continuous immunosuppression.
The folly of using results obtained with rodent models to guide clinical treatment decisions is self-evident. It also is obvious that neither the presence nor the quantity of donor leukocyte chimerism can be used per se in planning drug weaning protocols for patients. 
VII. THE GENETIC CONTROL OF TOLERANCE
It would be equally absurd to believe that the events after transplantation. including the development of tolerance to alloantigens, are not under genetic control. This genetic framework has been too well worked out during the last 40 years to warrant extensive citation. However, most of the evidence of a precision effect of MHC on the outcome of organ transplantation in large mammals has been obtained under conditions of a perfect or near-perfect donor-recipient compatibility with surprisingly little fall-off in survival expectations of human organ recipients at various lesser levels of mismatching, no matter how extreme the incompatibility [153] [154] [155] [156] [157] The two-way paradigm explains why. For all practical purposes, the one constant factor for induction of lasting transplantation tolerance has been chimerism, the effects of which far exceed in strength and complexity the mere presence of nonliving donor antigen. Consequently, successful organ transplantation requires conditions that allow assimilation 0 f the fragment of the donor immunological system introduced with the allograft into the preexisting recipient network, and vice versa. The subsequent reciprocal modulation of the large and the small immunological apparatus is determined within feasibility boundaries that are genetically proscribed for each.
In his recent review of two books on the history of immunology (160, 161] , Rosen remarked. "Having solved the problem of the molecular basis of specificity, immunology reached the end of its history" (\621. However. all properties of the immune system cannot be explained with the concept of a genetically "hard-wired self." Tauber has suggested that such a bias is derived from a Western individualistic philosophy of how humans relate to the world (28) . In our view, MHC did not evolve to permit immunological segregation but rather to meet the need of populations, not individuals, for immunological flexibility. In this context. the genetic issue is not self versus nonself so much as the ability of the population to adapt to change and the survival need for such maneuverability. Allograft rejection was, of course. an unforeseen by-product. and transplantation of surgically revascularized allografts was, in essence, the production and then control of an organ-specific autoimmune disease. Thus. contrary to Burnet's concern (29) . there were no biological rules that prohibited chimerism or successful organ transplantation.
VIII. THERAPEUTIC IMPLICATIONS
The two-way paradigm all6ws predictions about what can (and cannot) be accomplished with tolerance inducing strategies. all of which are auempts to alter the donor/recipient leukocyte interaction. It has been established that when both immunocyte populatlons are competent. and when lmmunosuppression IS delivered to the two arms equally, the microchimerism produced by organ transplantation can be greatly augmented by the coadministration of 3-6 x 10 8 /kg unmodified donor bone marrow cells without a significant risk of GVHD [163] . The presence of donor deoxyribonucleic acid (DNA) in the myeloid and erythroid colonies generated from recipients' peripheral blood mononuclear cells (PBMCs) by using standard clonal hematopoietic progenitor cell assays provided unequivocal evidence of engraftment [164] . These findings have been confirmed and extended by Garcia Morales et al. [165] , using innovative clonal hematopoietic progenitor cells assays.
Despite the increase of persistent chimerism to levels many times higher tha.n that in control patients neither the timing, severity, nor frequency of acute rejection has been different than in non-marrow-augmented control patients [163] [164] [165] (Figure 7) . It had not been anticipated that these endpoints would be altered. The hypotheses being tested are, first, that the threat of chronic organ rejection will be reduced. and. second, that the frequency of ultimate drug independence can be increased by achieving a higher persistent level of chimerism. An efficacy evaluation is expected to take 5 to 10 years, roughly the same time frame (Figure 6 ) delineated by three decades of clinical experience with MHC-incompatible liver and bone marrow transplantation [103] .
The administration of colony stimulating hematolymphopoietic growth factors (e.g., GM-CSF) or drugs like lisofylline (discussed earlier) is predicted to be without significant risk of GVHD if such chimerism augmenting treatment is imposed on both cell populations equally. In contrast. procedures that alter only one of the interacting arms must be approached with caution, as exemplified by the historical experience with GVHD after cytoablation and bone marrow transplantation. When the converse tactic of leukocyte-or T cell-specific depletion of intestinal The highest priority in transplantation today is the clinical development of xenografting techniques. Although the interspecies activation of complement may be preventable with the creation of transgenic or otherwise altered animal donors, it is naive to believe that the success of xenotransplantation procedures will not involve the manipulation and control of the same bidirectional immune reactions as with allografts and the ultimate establishment of stable chimerism.
IX. CONCLUSION
The unwarranted assumption that stem cell-driven hematolymphopoietic chimerism was irrelevant to successful whole organ transplantation as currently practiced led to alternative inadequate explanations of organ allograft acceptance. clouded the meaning of successful bone marrow transplantation, and precluded for more than three decades the development of a cardinal principle of transplantation. Recognition of this error and incorporation of the chimerism factor into a two-way paradigm have allowed previous enigmas of organ as well as bone marrow engraftment to be explained and should allow the vast foundation of basic immunology to be more meaningfully exploited in transplantation. In turn, experimental examination of the mechanisms of the two-way immune interaction implicit in this concept may further elucidate the meaning of selflnonself discrimination. 
